UK markets close in 3 hours 39 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
223.92-4.60 (-2.01%)
At close: 04:00PM EST
223.00 -0.92 (-0.41%)
After hours: 07:53PM EST
Full screen
Trade prices are not sourced from all markets
Previous close228.52
Bid221.47 x 1100
Ask224.50 x 800
Day's range221.75 - 229.04
52-week range221.72 - 468.55
Avg. volume1,164,744
Market cap32.892B
Beta (5Y monthly)0.39
PE ratio (TTM)11.61
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Motley Fool

    Should You Blame Biogen for Medicare Part B Premium Hikes?

    If you're enrolled in Medicare Part B, your premiums will increase quite a bit next year. The Centers for Medicare and Medicaid Services (CMS) singled out one drug as a key reason behind the coming hike: Biogen's (NASDAQ: BIIB) Alzheimer's disease drug Aduhelm. In this Motley Fool Live video recorded on Nov. 16, Fool contributors Keith Speights and Brian Orelli discuss whether beneficiaries should really blame Biogen for their higher Medicare Part B premiums.

  • Reuters

    Drugmakers cut prices by 62% on average to get China state insurance listing

    Pharmaceutical firms have agreed to cut prices by 61.7% on average for 67 medicines to be included in China's national medical insurance coverage in a new round of negotiations, Chinese authorities said on Friday. Inclusion on the National Reimbursement Drugs List has helped many global drugmakers such as Merck & Co Inc and Novartis AG book strong product sales growth in China in recent years, as their products have become more widely available. The newly added 67 medicines are branded drugs with no generic versions available in China and include blockbusters such as Eli Lilly & Co's psoriasis treatment Taltz and Johnson & Johnson's multiple myeloma drug Darzalex, according to the National Healthcare Security Administration (NHSA).

  • Zacks

    Sage (SAGE), Biogen (BIIB) Report Data on Depression Drug

    Sage Therapeutics (SAGE) and partner Biogen (BIIB) announce positive data from a cohort of an ongoing phase III study, currently evaluating their investigational major depressive disorder drug zuranolone.